ATRIAL FIBRILLATION IN PATIENTS WITH LEFT VENTRICULAR HYPERTROPHY: WHICH TACTICS IS OPTIMAL FOR RHYTHM CONTROL STRATEGY?


Citar

Texto integral

Acesso aberto Acesso aberto
Acesso é fechado Acesso está concedido
Acesso é fechado Acesso é pago ou somente para assinantes

Resumo

The most common cardiac rhythm disorder in patients with hypertrophic cardiomyopathy (HCM) patients is atrial fibrillation (AF), which is considered to be a main cause of further complications and readmissions. Current review analyzes modern rhythm control strategies in patients with HCM and AF, evaluates various available antiarrhythmic preparations (AAPs), possible complications associated with their use, and contraindications to them. The recurrence rate of AF can vary greatly after the chosen therapy. Several predictors of increased recurrence have been identified, including older age, left atrial dilatation, and the presence of fibrosis on MRI, but more evidence to prove them is needed to standardize the use of these factors in clinical practice. Modern physician needs to be aware of the therapeutic possibilities existing in the field of rhythm control strategies. Due to left ventricular hypertrophy (LVH) and fibrosis in HCM patients, the choice of antiarrhythmic therapy often becomes a difficult problem. Rhythm control strategy should be initiated in all symptomatic patients with HCM and newly diagnosed AF. Using of class IC or class III AAPs (sotalol) is limited in patients with significant LVH due to the lack of evidence for their use. Amiodarone, which has an unfavorable safety profile, is considered the only option for rhythm control in patients with HCM, but only a few small studies have investigated its use in this case. Randomized trials are needed to select an effective and safe rhythm control strategy in that type of patients.

Texto integral

Acesso é fechado

Sobre autores

Maria Kuznetsova

National Medical Research Center for Therapy and Preventive Medicine of the Ministry of Healthcare of Russia

Email: mkuznetsova@gnicpm.ru
PhD in Medicine, cardiologist of the highest category, deputy director for medical work

Aleksey Tarasov

National Medical Research Center for Therapy and Preventive Medicine of the Ministry of Healthcare of Russia

Email: a730tv@yandex.ru
Dr. med. habil., cardiologist of the highest category, head of the Department of surgical treatment of complicated cardiac arrhythmias and cardiac pacing

Diego Vinuesa

Peoples' Friendship University of Russia

Email: diegoismaelvinueza@gmail.com
resident physician in cardiology of the Department of internal medicine with a course in cardiology and functional diagnostics, Medical institute

Victor Sambrano

Peoples' Friendship University of Russia

Email: santiagozambrano_md@hotmail.com
resident doctor in the specialty «Cardiology» of the Department of internal medicine with a course of cardiology and functional diagnostics, Medical institute

Karapet Davtyan

National Medical Research Center for Therapy and Preventive Medicine of the Ministry of Healthcare of Russia

Dr. med. habil., professor, head of the Department of cardiac rhythm and conduction disorders

Oksana Drapkina

National Medical Research Center for Therapy and Preventive Medicine of the Ministry of Healthcare of Russia

Email: drapkina@bk.ru
Dr. med. habil., professor, academician of the RAS, chief external expert in therapy and general medical practice of the Ministry of Healthcare of Russia, Honored Doctor of the Russian Federation, director

Bibliografia

  1. Alphonse P., Virk S., Collins J. et al. Prognostic impact of atrial fibrillation in hypertrophic cardiomyopathy: A systematic review. Clin Res Cardiol. 2021; 110(4): 544-54. https://dx.doi.org/10.1007/s00392-020-01730-w.
  2. Monserrat L., Elliott P.M., Gimeno J.R. et al. Non-sustained ventricular tachycardia in hypertrophic cardiomyopathy: An independent marker of sudden death risk in young patients. J Am Coll Cardiol. 2013; 42(5): 873-79. https://dx.doi.org/10.1016/s0735-1097(03)00827-1.
  3. Authors/Task Force members; Elliott P.M., Anastasakis A., Borger M.A. et al. ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: The Task Force for the diagnosis and management of hypertrophic cardiomyopathy of the European Society of Cardiology (ESC). Eur Heart J. 2014; 35(39): 2733-79. https://dx.doi.org/10.1093/eurheartj/ehu284.
  4. Olivotto I., Cecchi F., Casey S.A. et al. Impact of atrial fibrillation on the clinical course of hypertrophic cardiomyopathy. Circulation. 2001; 104(21): 2517-24. https://dx.doi.org/10.1161/hc4601.097997.
  5. Wilke I., Witzel K., Munch J. et al. High incidence of de novo and subclinical atrial fibrillation in patients with hypertrophic cardiomyopathy and cardiac rhythm management device. J Cardiovasc Electrophysiol. 2016; 27(7): 779-84. https://dx.doi.org/10.1111/jce.12982.
  6. Maron B.J., Olivotto I., Bellone P. et al. Clinical profile of stroke in 900 patients with hypertrophic cardiomyopathy. J Am Coll Cardiol. 2002; 39(2): 301-7. https://dx.doi.org/10.1016/S0735-1097(01)01727-2.
  7. Patten M., Pecha S., Aydin A. Atrial fibrillation in hypertrophic cardiomyopathy: Diagnosis and considerations for management. J Atr Fibrillation. 2018; 10(5): 1 556. https://dx.doi.org/10.4022/jafib.1556.
  8. Kirchhof P., Andresen D., Bosch R. et al. Short-term versus long-term antiarrhythmic drug treatment after cardioversion of atrial fibrillation (Flec-SL): A prospective, randomised, open-label, blinded endpoint assessment trial. Lancet. 2012; 380(9838): 238-46. https://dx.doi.org/10.1016/S0140-6736(12)60570-4.
  9. Singh B.N., Singh S.N., Reda D.J. et al. Amiodarone versus sotalol for atrial fibrillation. N Engl J Med. 2005; 352(18): 1861-72. https://dx.doi.org/10.1056/nejmoa041705.
  10. Cosedis Nielsen J., Johannessen A., Raatikainen P. et al. Radiofrequency ablation as initial therapy in paroxysmal atrial fibrillation. N Engl J Med. 2012; 367(17): 1587-95. https://dx.doi.org/10.1056/nejmoa1113566.
  11. Rahimi K., Otto C.M. Heartbeat: Is atrial fibrillation ablation effective in patients with hypertrophic cardiomyopathy? Heart. 2016; 102(19): 1511-12. http://dx.doi.org/10.1136/heartjnl-2016-310468.
  12. Bonow R.O., Frederick T.M., Bacharach S.L. et al. Atrial systole and left ventricular filling in hypertrophic cardiomyopathy: Effect of verapamil. Am J Cardiol. 1983; 51(8): 1386-91. https://dx.doi.org/10.1016/0002-9149(83)90317-X.
  13. Opfermann U.T., Doll N., Walther T., Mohr F.W.Combined mitral valve repair, LVOT myectomy and left atrial cryoablation therapy.Interact Cardiovasc Thorac Surg. 2003; 2(4): 501-2. https://dx.doi.org/10.1016/s1569-9293(03)00129-4.
  14. Packer D.L., Mark D.B., Robb R.A. et al. Effect of catheter ablation vs antiarrhythmic drug therapy on mortality, stroke, bleeding, and cardiac arrest among patients with atrial fibrillation: The CABANA randomized clinical trial. JAMA. 2019; 321(13): 1261-74. https://dx.doi.org/10.1001/jama.2019.0693.
  15. Girolami F., Iascone M., Tomberli B. et al. Novel a-actinin 2 variant associated with familial hypertrophic cardiomyopathy and juvenile atrial arrhythmias: a massively parallel sequencing study. Circ Cardiovasc Genet. 2014; 7(6) :741-50. https://dx.doi.org/10.1161/circgenetics.113.000486.
  16. Gruver E.J., Fatkin D., Dodds G.A. et al. Familial hypertrophic cardiomyopathy and atrial fibrillation caused by Arg663His beta-cardiac myosin heavy chain mutation. Am J Cardiol. 1999; 83(12A): 13H-18H. https://dx.doi.org/10.1016/s0002-9149(99)00251-9.
  17. Pujadas S., Vidal-Perez R., Hidalgo A. et al. Correlation between myocardial fibrosis and the occurrence of atrial fibrillation in hypertrophic cardiomyopathy: A cardiac magnetic resonance imaging study. Eur J Radiol. 2010; 75(2): e88-91. https://dx.doi.org/10.1016/j.ejrad.2009.12.012.
  18. Bongini C., Ferrantini C., Girolami F. et al. Impact of genotype on the occurrence of atrial fibrillation in patients with hypertrophic cardiomyopathy. Am J Cardiol. 2016; 117(7): 1151-59. https://dx.doi.org/10.1016/j.amjcard.2015.12.058.
  19. Finocchiaro G., Sheikh N., Biagini E. et al. The electrocardiogram in the diagnosis and management of patients with hypertrophic cardiomyopathy. Heart Rhythm. 2020; 17(1): 142-51. https://dx.doi.org/10.1016/j.hrthm.2019.07.019.
  20. Peteiro J., Bouzas-Mosquera A., Fernandez X. et al. Prognostic value of exercise echocardiography in patients with hypertrophic cardiomyopathy. J Am Soc Echocardiogr. 2012; 25(2): 182-89. https://dx.doi.org/10.1016/j.echo.2011.11.005
  21. Llamas-Gomez H., Esteve Ruiz I., Romero Reyes M.J. et al. Atrial longitudinal strain and new onset of atrial fibrillation in a cohort of hypertrophic cardiomyopathy patients. Eur Heart J. 2021; 42(1): ehab724.1611. https://dx.doi.org/10.1093/eurheartj/ehab724.1611.
  22. Bravo P.E., Luo H.C., Pozios I. et al. Late gadolinium enhancement confined to the right ventricular insertion points in hypertrophic cardiomyopathy: An intermediate stage phenotype? Eur Heart J Cardiovasc Imaging. 2016; 17(3): 293-300. https://dx.doi.org/10.1093/ehjci/jev154.
  23. Maron B.J., Haas T.S., Maron M.S. et al. Left atrial remodeling in hypertrophic cardiomyopathy and susceptibility markers for atrial fibrillation identified by cardiovascular magnetic resonance. Am J Cardiol. 2014; 113(8): 1394-400. https://dx.doi.org/10.1016/j.amjcard.2013.12.045.
  24. Harris K.M., Spirito P., Maron M.S. et al. Prevalence, clinical profile, and significance of left ventricular remodeling in the end-stage phase of hypertrophic cardiomyopathy. Circulation. 2006; 114(3): 216-25. https://dx.doi.org/10.1161/circulationaha.105.583500.
  25. Савченко М.И., Ковалев Ю.Р., Кучинский А.П. Гипертрофическая кардиомиопатия: фиброз или гипертрофия. Артериальная гипертензия. 2013; 19(2): 148-155. [Savchenko M.I., Kovalev Yu.R., Kuchinsky A.P. Hypertrophic cardiomyopathy: fibrosis or hypertrophy. Arterial'naya gipertenziya = Arterial Hypertension. 2013; 19(2): 148-155 (In Russ.)]. EDN: QAXQXL.
  26. Spoladore R., Maron M.S., D'Amato R. et al. Pharmacological treatment options for hypertrophic cardiomyopathy: High time for evidence. Eur Heart J. 2012; 33(14): 1724-33. https://dx.doi.org/10.1093/eurheartj/ehs150.
  27. Dan G.A., Martinez-Rubio A., Agewall S. et al.; ESC Scientific Document Group. Antiarrhythmic drugs - clinical use and clinical decision making: A consensus document from the European Heart Rhythm Association (EHRA) and European Society of Cardiology (ESC) Working Group on Cardiovascular Pharmacology, endorsed by the Heart Rhythm Society (HRS), Asia-Pacific Heart Rhythm Society (APHRS) and International Society of Cardiovascular Pharmacotherapy (ISCP). Europace. 2018; 20(5): 731-32an. https://dx.doi.org/10.1093/europace/eux373.
  28. Chung R., Houghtaling P.L., Tchou M. et al. Left ventricular hypertrophy and antiarrhythmic drugs in atrial fibrillation: impact on mortality. Pacing Clin Electrophysiol. 2014; 37(10): 1338-48. https://dx.doi.org/10.1111/pace.12426.
  29. Миллер О.Н., Старичков С.А., Поздняков Ю.М. с соавт. Эффективность и безопасность применения пропафенона (Пропанорма®) и амиодарона (Кордарона®) у больных с фибрилляцией предсердий на фоне артериальной гипертонии, ишемической болезни сердца и хронической сердечной недостаточности с сохраненной систолической функцией левого желудочка. Российский кардиологический журнал. 2010; 15(4): 55-71
  30. Габрусенко С.А., Гудкова А.Я., Козиолова Н.А. с соавт. Гипертрофическая кардиомиопатия. Клинические рекомендации 2020. Российский кардиологический журнал. 2021; 26(5): 269-334
  31. Santangeli P., Di Biase L., Themistoclakis S. et al. Catheter ablation of atrial fibrillation in hypertrophic cardiomyopathy: Long-term outcomes and mechanisms of arrhythmia recurrence. Circ Arrhythm Electrophysiol. 2013;6(6): 1089-94. https://dx.doi.org/10.1161/circep.113.000339.
  32. Cochet H., Morlon L., Vega M.-P. et al. Predictors of future onset of atrial fibrillation in hypertrophic cardiomyopathy. Arch Cardiovasc Dis. 2018; 111(10): 591-600. https://dx.doi.org/10.1016/j.acvd.2018.03.007.
  33. Couto Pereira S., Rigueira J., Placido R. et al. Hypertrophic cardiomyopathy: CMR to predict dysrhythmic events. Eur Heart J Cardiovasc Imaging. 2022; 23(1): jeab289.334. https://dx.doi.org/10.1093/ehjci/jeab289.334
  34. Castelo A., Rosa S.A., Fiarresga A. et al. Late gadolinium enhancement in the left ventricular wall is associated with atrial fibrillation in patients with hypertrophic cardiomyopathy.Int J Cardiovasc Imaging. (2022). https://dx.doi.org/10.1007/s10554-022-02642-8.

Arquivos suplementares

Arquivos suplementares
Ação
1. JATS XML
Baixar

Declaração de direitos autorais © Bionika Media, 2022

Este site utiliza cookies

Ao continuar usando nosso site, você concorda com o procedimento de cookies que mantêm o site funcionando normalmente.

Informação sobre cookies